14266
document
Oral ondansetron in the prevention of postoperative nausea and vomiting . The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized , double-blind , placebo-controlled , multi-centre studies . The first study compared ondansetron 1 , 8 and 16 mg to placebo , and the second study compared 8 mg ondansetron to placebo . Both studies included ASA Class I-III female patients about to undergo major abdominal gynaecological surgery or vaginal hysterectomy . In the first study , the 8 and 16 mg ondansetron groups had a significantly lower incidence of nausea and vomiting in the 0-24 h period following recovery from anaesthesia than the placebo group . Ondansetron 8 mg three times daily was also significantly better than placebo in the second study . Side-effects mainly consisted of constipation , headache , and asymptomatic elevation of liver enzymes . The incidence of side-effects was similar in ondansetron- and placebo-treated patients . There appeared to be no clinically important benefit of the 16 mg three times daily ondansetron regimen over the 8 mg three times daily dose , therefore 8 mg three times daily is recommended as the optimal oral dose in the prevention of postoperative nausea and vomiting .
14267
Intervention_Pharmacological
ondansetron
14268
Intervention_Control
placebo-controlled
14269
Intervention_Pharmacological
ondansetron 1 , 8 and 16 mg
14270
Intervention_Control
placebo
14271
Intervention_Pharmacological
8 mg ondansetron
14272
Intervention_Control
placebo
14273
Intervention_Pharmacological
8 and 16 mg ondansetron groups
14274
Intervention_Control
placebo
14275
Intervention_Pharmacological
Ondansetron
14276
Intervention_Pharmacological
ondansetron
14277
Outcome_Physical
prevention of postoperative nausea and vomiting
14278
Outcome_Physical
postoperative nausea and vomiting
14279
Outcome_Physical
incidence of nausea and vomiting
14280
Outcome_Adverse-effects
Side-effects
14281
Outcome_Adverse-effects
constipation , headache , and asymptomatic elevation of liver enzymes
14282
Outcome_Adverse-effects
side-effects
14283
Outcome_Other
clinically important benefit
14284
Outcome_Physical
postoperative nausea and vomiting
14285
Participant_Condition
ASA Class I-III
14286
Participant_Sex
female
14287
Participant_Condition
patients about to undergo major abdominal gynaecological surgery or vaginal hysterectomy